Nice reviews 5 ovarian cancer drugs

Source: Ding Xiangyuan 2014-12-26 the National Institute of health care optimization (NICE) is reviewing the guidelines for the use of five drugs to determine whether these drugs should be recommended as treatment options for patients with ovarian cancer who relapse after previous chemotherapy Nice is considering the application of gemcitabine, paclitaxel, polyethylene glycol liposome doxorubicin hydrochloride (pdlh), topotecan and trabectedin for this indication The agency said in the final guidance that paclitaxel and pLDH are cost-effective drugs and should continue to be recommended for routine use in NHS The draft guidelines also recommend the combination of pLDH and platinum chemotherapy Although pLDH is not currently licensed for this indication, it has been shown to be one of the two most effective treatment options for recurrent ovarian cancer, and specific agreements from the Ministry of health have led to this recommendation by the nice evaluation committee However, the draft guidelines do not recommend gemcitabine, topotecan or trobetadine for ovarian cancer at this stage At least six months after platinum based chemotherapy, the drugs showed little benefit to patients when the disease first recurred, compared with other options, the agency said The evaluation committee did not recommend these drugs for the treatment of advanced ovarian cancer because there is no evidence to predict their clinical and cost-effectiveness, the agency added For patients with ovarian cancer who do not respond to platinum based chemotherapy or relapse 6 months after this treatment, the Committee believes that pLDH and paclitaxel may be recommended, but topotecan is not a cost-effective drug "Ovarian cancer is one of the most common cancers in women, and for most of these patients, their cancer recurred within two years of completion of treatment These women, like all other NHS patients, should have access to drugs that will have the most important impact on their lives and that the NHS can afford, "said nice chief executive Dillon He added that the draft recommendation had been based on the best evidence from manufacturers, independent assessment organizations, health care professionals and patient organizations Manufacturers and other registered assessment stakeholder organizations may appeal these recommendations to the extent that they believe that nice's actions are unfair or beyond their competence Otherwise, the draft guide will continue to be published next year, Andrew said.